Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL12B Polymorphism and Humira Response in Psoriasis and Psoriatic Arthritis
NCT07128472Recruiting
- Sponsor
- South Valley University
- Start
- Aug 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of adalimumab in psoriasis and psoriatic arthritis (PsA) (2 arms), sponsored by South Valley University. Primary endpoint: Treatment of Psoriasis and Psoriatic Arthritis at 3 months. Started Aug 2025; status: recruiting.
02
Drugs
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07128472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128472.